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Whole-brainirradiation(WBI)representstheprimarymodeoftreatmentforbrainmetastases;about200000patientsreceiveWBI
each year in the USA. Up to 50% of adult and 100% of pediatric brain cancer patients who survive >6 months post-WBI will suﬀer
from a progressive, cognitive impairment. At present, there are no proven long-term treatments or preventive strategies for this
signiﬁcant radiation-induced late eﬀect. Recent studies suggest that the pathogenesis of radiation-induced brain injury involves
WBI-mediated increases in oxidative stress and/or inﬂammatory responses in the brain. Therefore, anti-inﬂammatory strategies
can be employed to modulate radiation-induced brain injury. Peroxisomal proliferator-activated receptors (PPARs) are ligand-
activated transcription factors that belong to the steroid/thyroid hormone nuclear receptor superfamily. Although traditionally
known to play a role in metabolism, increasing evidence suggests a role for PPARs in regulating the response to inﬂammation and
oxidative injury. PPAR agonists have been shown to cross the blood-brain barrier and confer neuroprotection in animal models of
CNS disorders such as stroke, multiple sclerosis and Parkinson’s disease. However, the role of PPARs in radiation-induced brain
injury is unclear. In this manuscript, we review the current knowledge and the emerging insights about the role of PPARs in
modulating radiation-induced brain injury.
1.Introduction
PPARs are ligand-activated transcription factors that belong
to the steroid/thyroid hormone superfamily of nuclear
receptors [1, 2]. To date, three PPAR isotypes have been
identiﬁed—PPARα (NR1C1), PPARβ (NR1C2 or PPARδ),
and PPARγ (NR1C3) [3]. Each is encoded by a separate
gene, and each has a unique tissue distribution pattern [4,
5]. PPARs regulate gene transcription by heterodimerizing
with the retinoid X receptor (RXR) and binding to speciﬁc
consensus sequences (termed PPAR response elements,
PPREs) in the enhancer regions of genes [6]. PPREs consist
of a direct repeat (DR) of the nuclear receptor hexameric
recognition sequence AGGTCA separated by one or two
nucleotides (DR-1 or DR-2) [6]. The protein structure of the
PPAR isotypes reveals two well-characterized domains—a
highlyconservedDNAbindingdomainandaligand-binding
domain(LBD)thatislesswellconservedacrossthesubtypes.
Variation in the sequence of amino acids that line the ligand-
binding pocket is a major determinant of ligand isotype
speciﬁcity [7, 8]. In the absence of ligand binding, PPAR-
RXR heterodimers are bound to corepressor proteins such
as HDACs and N-CoRs that maintain the chromatin in the
condensed state and inhibit the transcriptional apparatus
from assembling. Upon ligand binding, PPARs undergo
a conformational change that leads to dissociation of the
corepressor proteins. Subsequently, the ligand-bound PPARs
complex with coactivator proteins such as p300 leading2 PPAR Research
to nucleosome remodeling and transcriptional preinitiation
complex assembly on target gene promoters [7]. The tran-
scriptional response is strongly inﬂuenced by the structure
of the promoter and the expression levels of coactivators and
corepressors in a given cell-type [9].
2. TissueDistributionand Physiological
Role of PPARs
PPARα is predominantly expressed in tissues that catabolize
high amounts of fatty acids such as the liver, skeletal muscle,
and heart and regulates many metabolic pathways, including
activation of fatty acid β-oxidation and apolipoprotein
expression [10]. Natural ligands such as eicosanoids, mono-
and polyunsaturated fatty acids and long-chain fatty acyl-
CoenzymeA can bind and activate PPARα [7]. Hypolipi-
demic ﬁbrate drugs that are routinely prescribed to patients
for lowering triglyceride and cholesterol levels have been
demonstrated to be synthetic ligands of PPARα [11, 12].
PPARγ is most abundantly expressed in fat cells, the
large intestine, and cells of the monocyte lineage. It is
primarily involved in the general transcriptional control of
adipocyte diﬀerentiation, immune responses, and glucose
homeostasis [13, 14]. PPARγ exists as two distinct forms,
γ1a n dγ2, which arise by diﬀerential transcription start
sites and alternative splicing [15]. Whereas PPARγ1i sl o w
in most tissues, PPARγ2 is fat-selective and is expressed at
very high levels in adipose tissue [14]. PPARγ is bound and
activated by several naturally occurring compounds, such as
the eicosanoids 9- and 13-hydroxyoctadecadienoic acids [8].
Morerecently,atypeofnitratedlipids knownasnitroalkenes
has been demonstrated to be potent, endogenous ligands
of PPARγ [16]. In addition, several high-aﬃnity synthetic
PPARγ agonists have been synthesized, including the thiazo-
lidinedione (TZD) class of compounds [17], which are used
clinicallyasinsulinsensitizersinpatientswithtype2diabetes
[18], and certain nonsteroidal antiinﬂammatory drugs [19].
Unlike the PPARα and PPARγ isotypes, the expression
of PPARδ appears to be ubiquitous. Ligands of PPARδ
include fatty acids such as bromopalmitate [20] and the
prostanoid prostacyclin PGI2 [21]. Studies suggest key roles
for PPARδ in proliferation [22], diﬀerentiation, and survival
as well as in embryonic development and fatty acid β-
oxidation in skeletal muscles and adipose tissues [22]. More
recently, PPARδ agonists have been shown to enhance
oligodendrocyte maturation and diﬀerentiation [23]. Mice
that are knocked-out for PPARδ have altered myelination
in the corpus callosum suggesting a role for PPARδ in
myelination [24].
3.PPARs inthe Central NervousSystem
All PPAR isotypes have been identiﬁed in the rodent brain,
and their expression has been shown to peak between day
13.5 and 18.5 of gestation. The degree of expression and
speciﬁc localization varies among the receptors. PPARδ
appears to be expressed ubiquitously in all regions of the
brain [4], primarily in oligodendrocytes and neurons [25]
and to a lesser extent in astrocytes [4]. In the spinal cord
white matter, expression is localized to oligodendrocytes
[26]. PPARα expression in the brain appears limited to the
olfactory bulbs, hippocampus, and cerebellum, primarily in
cerebellar granule neurons (CGNs) [5] and astrocytes. In the
spinal cord white matter, expression of PPARα is localized to
astrocytes [26]. PPARγ has been observed, albeit at relatively
low levels, in the hippocampus, cerebellum as well as in
cortical astrocytes and CGN [4]. All three PPAR isoforms are
expressed in the microglia [27].
All PPAR isoforms have been proposed to play an
important role in the developing and adult brain [28].
PPARα has been shown to play a major role in acetylcholine
biosynthesis, excitatory amino acid neurotransmission, and
defense against oxidative stress [29]. PPARγ is coexpressed
along with dopominergic receptors in several regions of
the brain suggesting that it could regulate the action of
dopamine on gene transcription [29]. PPARδ-mediated
transcriptional upregulation of Acyl-CoA synthetase 2 medi-
atesfattyacidutilizationandplaysanimportantroleinbrain
lipid metabolism. Experiments using neurosphere cultures
derived from mouse neural stem cells isolated from the
subventricular zone (SVZ) have demonstrated that PPARs
regulate the proliferation and fate of these cells [30, 31].
4.Anti-Inﬂammatory/NeuroprotectiveRole
of PPARs in Neurodegenerative Disorders
In addition to their well-known functions on cellular
metabolism, PPARs have been shown to play a major role
in inﬂammation. The anti-inﬂammatory functions of PPARs
in several peripheral tissues have been reviewed elsewhere
[2, 32] and beyond the scope of this review. With reference
to the CNS, several studies have documented the anti-
inﬂammatory and neuroprotective eﬀects of PPAR ligands in
a number of neuropathological conditions [27, 33].
In vitro models of Alzheimer’s disease (AD), PPARγ ago-
nists inhibited the neuronal death induced by the amyloid-
β (Aβ) peptide by inhibiting the microglial and mono-
cytic proinﬂammatory response and astrocytic proliferation
[34]. In vivo, oral administration of the PPARγ agonist
pioglitazone reduced glial activation and the accumulation
of Aβ-positive plaques in the hippocampus and cortex
[35, 36]. In a clinical trial involving 500 AD patients, a
signiﬁcant improvement in cognitive function was observed
following treatment with the PPARγ agonist, rosiglitazone
for 6 months [37].
In a mouse model of Parkinson’s disease, oral admin-
istration of pioglitazone inhibited the glial activation
induced by the neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-
tetrahydropyridine (MPTP) and prevented the loss of
dopominergic neurons in the substantia nigra pars com-
pacta. Mechanistically, the neuronal death was prevented
by (i) inhibiting the nuclear translocation of the redox-
regulated proinﬂammatory transcription factor NF-κBs u b -
unit p65 and (ii) preventing the subsequent induction of
inducible nitric oxide synthase (iNOS) gene [38]. Similar
protective eﬀects on dopominergic neurons were demon-
strated following administration of the PPARα agonist
fenoﬁbrate [39].PPAR Research 3
PPAR agonists have also been shown to reduce the
severity of cerebral ischemic injury in rodents. Oral adminis-
tration of PPARα agonists decreased the incidence of stroke
in apolipoprotein-E deﬁcient mice and reduced the cerebral
infarct volume in wild-type mice following transient middle
cerebral artery occlusion (MCAO) [40, 41]. These eﬀects
were associated with decreased oxidative stress and adhesion
molecule expression in the brain [40]. Other studies have
reported that administration of PPARα agonists either prior
to cerebral ischemia or during the reperfusion period can
also have a neuroprotective eﬀect [42, 43]. Likewise, admin-
istration of the PPARγ agonists troglitazone or pioglitazone,
or the PPARδ agonists L-165041 or GW501516, prior to or
during transient MCAO reduces the infarct volume [44–46].
In the mouse model of multiple sclerosis (MS), exper-
imental autoimmune encephalomyelitis (EAE), PPAR ago-
nists have been shown to delay the onset and reduce
the severity of the disease. PPARα agonists inhibited the
proliferation of CD4+ T-cells and shifted their diﬀerenti-
ation pattern from the proinﬂammatory Th1-type to the
anti-inﬂammatory Th2-type cells [47]. In addition, oral
administration of the PPARα agonists, gemﬁbrozil and
fenoﬁbrate, alleviated the clinical symptoms of EAE [47, 48].
Administering the PPARδ agonist GW0742 in the mouse
diet during the peak of EAE can improve clinical recovery,
partly by reducing lymphocyte inﬁltration into the CNS
and by decreasing resident glial activation [49]. Numerous
research studies have demonstrated the anti-inﬂammatory
and neuroprotective role of PPARγ agonists in reducing the
neurological symptoms of chronic progressive and relapsing
forms of EAE [50–52].
Since resident glial cell inﬂammation and immune cell
inﬁltration into the brain are considered hallmarks of several
neuroinﬂammatory disorders, numerous research groups
have hypothesized that the neuroprotective eﬀects of PPAR
agonists might result, in part, from inhibition of proin-
ﬂammatory responses during the CNS pathology. Consistent
with this hypothesis, PPAR agonists have been shown to
inhibit myelin oligodendrocyte glycoprotein-, cytokine-, and
lipopolysaccharide-induced increases in proinﬂammatory
mediators such as tumor necrosis factor alpha (TNFα),
members of the interleukin (IL) family such as interleukin
1b e t a( I L - 1 β) and IL-12, cyclooxygenase-2 (Cox-2), iNOS,
and interferon gamma (IFN-γ) as well as the expression
of adhesion molecules such as monocyte chemoattractant
protein-1 (MCP-1) in the astrocytes, microglia, and T-cells
in vitro [53–57].
Taken together, these data suggest that PPAR agonists
show promise as eﬃcacious anti-inﬂammatory agents in
ameliorating the clinical symptoms and disease severity of a
variety of CNS pathologies.
5. Whole-Brain Irradiationand
Radiation-InducedBrain Injury
Ongoing advancements in cancer treatment and healthcare
have led to an increase in the long-term survivors of cancer;
>67% of adult and >75% of pediatric cancer patients will
survive longer than 5 years after initial diagnosis. As a result,
late eﬀects remain a signiﬁcant risk for these ∼11 million
cancer survivors. Given the increasing population of long-
term survivors, the need to mitigate or treat late eﬀects has
emerged as a primary area of research in radiation biology
[58, 59].
The total dose of radiation therapy that can be admin-
istered safely to the brains of patients presenting with
primary or metastatic brain tumors is limited by the risk of
normal brain morbidity. The need to both understand and
minimize the side eﬀects of brain irradiation is intensiﬁed
by the ever-increasing number of patients with secondary
brain metastases (mets) that require treatment with partial
or whole-brain irradiation (WBI). Of the ∼1500000 new
cancer patients diagnosed in 2008 [60], up to 30% will
develop brain mets [61, 62], making this the 2nd most
common site of metastatic cancer, the most common
neurological manifestation of cancer, and a cancer problem
more common than newly diagnosed lung, breast, and
prostate cancer combined. The annual incidence in the US
appears to be increasing, as a result of an aging population,
better treatment of systemic cancer, and the application of
superior imaging techniques such as magnetic resonance
imaging (MRI) to detect smaller and micrometastatic lesions
in asymptomatic patients [63]. WBI is the primary mode
of treatment for brain mets; up to 170000 individuals will
ultimately be treated with large ﬁeld or WBI each year in the
USA. Over half of these patients will survive long enough to
develop radiation-induced brain injury, including cognitive
impairment. Presently, there are no successful long-term
treatments or eﬀective preventive strategies for radiation-
induced brain injury [64].
Classically, based on the time of expression, radiation-
induced brain injury has been subdivided into acute,
subacute (early delayed), and late delayed responses [65].
Acute injury is expressed days to weeks after irradia-
tion and is often characterized by drowsiness, vomiting,
headache, and nausea. This type of injury can be treated
with corticosteroids and is fairly uncommon under current
radiotherapyregimens[65,66].Earlydelayedinjurytypically
occurs from 1- to 6- months postradiation therapy and
can involve transient demyelination, short-term memory
loss, fatigability, and somnolence. While both these early
injuries can result in severe reactions, they are normally
reversible and resolve spontaneously. In sharp contrast, late
delayed eﬀects, distinguished by demyelination, vascular
abnormalities and ultimate radionecrosis of the white matter
are observed >6 months postirradiation and are usually
irreversible and progressive [67]. Intellectual deterioration is
also seen in patients receiving brain irradiation [68]. Data
suggestthat20%–50% ofbraintumorpatients whoarelong-
term survivors suﬀerfromprogressivecognitivedysfunction,
ranging from mild lassitude to signiﬁcant memory loss and
severe dementia [69–72]. More importantly, in both clinical
and preclinical models, the cognitive impairment has been
shown to occur in the absence of gross histopathological and
radiographic alterations [73–75].4 PPAR Research
6. Mechanisms of Radiation-Induced
Brain Injury:Role of OxidativeStress,
Neuroinﬂammation, and Impaired
Neurogenesis
Conventionally, late eﬀects were thought to be the conse-
quence of a reduction in the number of surviving clonogens
of either the parenchymal or the vascular target cell popu-
lations [65, 76]. Radiation-induced late normal tissue injury
was considered to be inevitable, progressive, and untreatable.
However, recent data suggest that this view is over-simplistic
andthatradiation-injuryinvolvescomplex,intercellular,and
intracellular interactions between various cell types [59, 65,
77–79] (in the brain these include astrocytes, microglia,
neurons,etc.)withinanorganandcanbemodulated[59].In
general,irradiatinglateresponding normaltissuesishypoth-
esizedtoactivateautocrineandparacrinesignaltransduction
events that initiate downstream reactive processes marked
by a persistent oxidative stress and cytokine production
ultimately contributing to tissue injury. Although the cel-
lular, molecular, and biochemical mechanisms of radiation-
induced brain injury are ill-deﬁned, several studies lend
support to the hypothesis that such an injury is driven,
in part, via increased oxidative stress and/or inﬂammation
[73, 80–83].
Irradiating one hemisphere of postnatal day 8 rats
or of postnatal day 10 mice with a single dose of 4–
12Gy of 4 MV X-rays led to time-dependent increases in
nitrotyrosine, a marker for protein nitrosylation, in the SVZ
and the granule cell layer (GCL) of the hippocampus 2–
12 hours postirradiation [84]. WBI of the mouse brain
with a single dose of 6Gy led to a signiﬁcant increase in
markers of lipid peroxidation and DNA oxidation such as 4-
hydroxynonenal and 8-hydroxy-2 -deoxyguanosine, respec-
tively, 1-month postirradiation in the dentate gyrus (DG),
and hilus of the hippocampus [85]. In addition to their
direct damaging eﬀects on the DNA, lipids, and proteins,
reactive oxygen species can act as second messengers to
initiate neuroinﬂammation [86].
Although the brain traditionally has been considered to
be immune-privileged, it is widely accepted now that the
brain does exhibit inﬂammation [87]. An acute molecular
response characterized by increased expression of inﬂamma-
tory cytokines/mediators such as TNFα,I L - 1 β, intracellular
adhesion molecule-1 (ICAM-1), Cox-2, and activation of
transcription factors such as NF-κB and activator protein-
1 (AP-1) is observed within hours of irradiating the rodent
brain [88–90]. In addition, a chronic elevation of TNFα
has been observed in the mouse brain up to 6-month
postirradiation [91].
More recently, the detrimental eﬀect of WBI on ongoing
hippocampal neurogenesis and the associated neuroinﬂam-
matory response characterized by activated microglia have
been proposed as a key mechanism of radiation-induced
cognitive impairment [73, 92]. The hippocampus is situated
in the medial-temporal lobe and is one of two regions
in the mammalian brain where active neurogenesis occurs
throughout adulthood. Neurogenesis is a complex multistep
process which starts with the proliferation of the neural
precursor cells residing in a specialized region called the
subgranular zone (SGZ) of the hippocampus, followed by
commitment to a neuronal phenotype, physiological, and
morphological maturation with the development of synaptic
andelectrophysiologicalpropertiesandendingwiththeinte-
gration of a functional neuron into the GCL [93]. Adult neu-
rogenesishasbeenshowntoplayanimportantroleincertain
types of hippocampal-dependent cognitive function [94].
One of the earliest observations that led to the proposed
involvement of the hippocampus in radiation-induced brain
injury was that the extent of cognitive impairment expe-
rienced by patients receiving radiotherapy correlated with
the dose delivered to the medial-temporal lobe [95]. Sub-
sequently, experimental studies have demonstrated that the
neural precursor cells in the SGZ are extremely sensitive to
radiation [80]. In vitro, irradiation reduces the proliferative
capacity of cultured neural precursor cells [96]. In vivo, the
ability of these precursor cells to give rise to new neurons
in the GCL is signiﬁcantly ablated by WBI [80, 96]. More
importantly, the WBI-induced decrease in neurogenesis is
associated with deﬁcits in hippocampal-dependent spatial
learning and memory tasks in mice [97–99]. Furthermore,
the deleterious eﬀect of WBI on hippocampal neurogenesis
was associated with an increase in the number of activated
microglia, suggesting an inﬂammatory response in the brain
following irradiation [80, 96, 98]. A role for the brain
microenvironment in the ablation of neurogenesis was fur-
ther supported by the demonstration that neural precursor
cells isolated from nonirradiated brains failed to give rise
to new neurons when transplanted into irradiated brains
[96]. A negative correlation between activated microglia
and hippocampal neurogenesis has been demonstrated, sug-
gesting that the WBI-induced neuroinﬂammatory response
could lead to the impaired neurogenesis [80, 96, 100].
Moreover, administration of the anti-inﬂammatory drug,
indomethacin, decreased radiation-induced microglial acti-
vation and partially restored neurogenesis [81]. Together,
these data suggest that altered neurogenesis as a result
of oxidative stress and/or neuroinﬂammation is one of
the mechanisms of radiation-induced brain injury. Thus,
anti-inﬂammatory strategies might be useful in preventing
radiation-induced late eﬀects in the brain.
An additional and intriguing aspect of inﬂammation
is the putative link between inﬂammation and impaired
PPAR expression. Analysis of gene expression in postmortem
brain tissue obtained from AD patients revealed signiﬁcant
decreases in PPARα and PPARδ gene expression, determined
using real time quantitative PCR [101]. Preliminary studies
from our own laboratory indicate that treating rat brain
microvascular endothelial cells with ionizing radiation or
hydrogen peroxide leads to a rapid and signiﬁcant reduction
in PPARγ mRNA and protein (unpublished data). Similar
c h a n g e sh a v eb e e no b s e r v e di nv i v o ;o n ey e a ra f t e ra
fractionated dose of 40Gy γ-rays, PPARγ gene expression
was markedly lower than that observed in age-matched
sham-irradiated rat brains. Although preliminary, these data
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to reduce PPAR expression within hours to several days of
treatment in the kidney [102] and the colon [103].
Given that several PPAR agonists are potent neuro-
protective/anti-inﬂammatory agents in several neuroinﬂam-
matory disorders, we hypothesized that activation of PPARs
will ameliorate the WBI-induced brain injury.
7. Effect of PPAR Agonists on
Radiation-InducedBrain Injury
7.1. In Vitro Studies. A growing body of evidence suggests
that the microglial proinﬂammatory response following
radiation contributes to the observed radiation-induced late
eﬀects. In vitro studies suggest that irradiating microglia
leads to a marked increase in expression of proinﬂammatory
genes including TNFα,I L - 1 β, IL-6, and Cox-2 [104–106].
Radiation-induced expression of microglial TNFα and IL-1β
has been shown to enhance leukocyte adhesion in the brain,
partly via increased expression of ICAM-1 in astrocytes
[104]. Cox-2-mediated production of prostaglandin E2,
TNFα,a n dI L - 1 β from the conditioned media of irradiated
BV-2 cellshas been shown to induce astrogliosis [106]. These
studies are supported by in vivo experiments in rodents
which indicate that brain irradiation leads to a marked
increase in microglial activation associated with both a con-
comitant decrease in neurogenesis in the hippocampus and
spatial memory retention deﬁcits as mentioned previously
[97–99]. Thus, modulating the microglial proinﬂammatory
response presents a promising approach to ameliorate
radiation-induced brain injury.
Extendingpreviousﬁndings,weobservedthatirradiating
BV-2 microglial cells led to a signiﬁcant increase in TNFα
and IL-1β gene expression and Cox-2 protein levels [107].
The promoter regions of TNFα,I L - 1 β, and Cox-2 contain
numerous transcription factor binding sites including AP-
1a n dN F - κB and numerous reports suggest that their
expressioninthemicrogliaisregulatedbythesetranscription
factors [108–112] . Consistent with this, marked increases in
the DNA binding activity of AP-1 and NF-κB as early as 30-
minutespostirradiationwereobservedinthemicroglialcells.
Moreover,usingspeciﬁcinhibitorsofAP-1andNF-κB, it was
demonstrated that the radiation-induced increase in TNFα
and Cox-2 expression was AP-1 mediated while that of IL-1β
was mediated by both NF-κB and AP-1.
Giventhepotentanti-inﬂammatorypropertiesofPPARα
ligands in a variety of cell types including microglia [54,
55, 113], we hypothesized that activation of PPARα in the
microglia would inhibit the radiation-induced proinﬂam-
matory response. Indeed, the radiation-induced increases
in TNFα,I L - 1 β gene expression, and Cox-2 protein were
signiﬁcantly inhibited by the PPARα agonists, GW7647, and
fenoﬁbrate. Mechanistically, PPARα agonists prevented the
activation of AP-1 (by inhibiting nuclear c-jun phosphory-
lation) and NF-κB (by preventing p65 nuclear translocation)
followingirradiationtherebyinhibitingthemicroglialproin-
ﬂammatory response [107]. These ﬁndings emphasize the
pleiotropic eﬀects of PPARα agonists in response to inﬂam-
mation as they target multiple proinﬂammatory microglial
cytokines that might be involved in the development and
progression of radiation-induced brain injury.
7.2. In Vivo Studies. The potent in vitro eﬃcacy of PPARα
ligands in modulating the radiation-induced microglial
proinﬂammatory response, along with the negative cor-
relation between microglial activation and hippocampal
neurogenesis, led to the hypothesis that activation of PPARα
in vivo would prevent the detrimental eﬀect of WBI on
neurogenesis and inhibit microglial activation (Ramanan et
al. unpublished data). In this study, wild-type (WT) mice
weredividedinto4groups:(1)Sham-irradiationandcontrol
diet, (2) Sham-irradiation and fenoﬁbrate (Fen; 0.2% w/w),
(3) WBI (delivered as a single dose of 10Gy γ-rays with
half the dose (5Gy) delivered to each side of the head)
and control diet, (4) WBI and fenoﬁbrate. For measuring
neurogenesis in the DG, all groups of mice received I.P
injections of bromodeoxyuridine (BrdU; 50mg/Kg body
weight) to label the surviving neural precursor cells in
the SGZ at 1 month post-WBI (as previously reported in
[80, 96, 98]). The number of newborn neurons arising
out of these surviving cells was assessed 2-month post-
WBI by using double immunoﬂuorescence to detect BrdU
and NeuN (a neuronal marker). Consistent with previous
ﬁndings [80, 96], WBI led to a signiﬁcant decrease in the
number of newborn neurons in the DG that was prevented
in the irradiated mice that received fenoﬁbrate in their
diet. Furthermore, fenoﬁbrate increased the total number of
BrdU+ cells in the DG of irradiated animals, suggesting that
the PPARα agonist promoted the survival of newborn cells
following irradiation.
Fortheassessmentofneuroinﬂammation,brainsisolated
either 1-week or 2-month post-WBI were subjected to stain-
ing with anti-CD68 antibody to label activated microglia.
Consistent with our hypothesis, fenoﬁbrate inhibited the
WBI-induced increase in number of activated microglia at 1-
week post-WBI. Therefore, the preservation of hippocampal
neurogenesis by fenoﬁbrate is associated with decreased
microglial activation following WBI. Moreover, the number
of activated microglia returned to control levels by 2 -
month post-WBI, the time point at which we observed a
signiﬁcant decrease in the number of newborn neurons.
Thus, the radiation-induced neuroinﬂammatory response
characterized by increased microglial activation might be an
early event and could be one of the key components driving
the detrimental eﬀects of radiation on ongoing hippocampal
neurogenesis.
Some studies have documented that fenoﬁbrate can act
independently of PPARα[48,114,115]. To addressthis issue,
the studies above were replicated in PPARα knock-out (KO)
mice.ThegeneticablationofPP ARαpreventedtheprotective
eﬀect of fenoﬁbrate following WBI. These ﬁndings highlight
the critical role played by PPARα in modulating radiation-
induced brain injury as well as providing mechanistic insight
into the neuroprotective and anti-inﬂammatory properties
of fenoﬁbrate.
A striking diﬀerence was observed in the response of the
microglial cells to WBI between the WT and PPARα KO
mice. Whereas the number of activated microglia returned6 PPAR Research
to control levels by 2 -month post-WBI in the WT mice,
activated microglia remained signiﬁcantly elevated in the KO
mice. This suggests that the KO mice show a sustained neu-
roinﬂammatory response following WBI. Consistent with
these data, preliminary ﬁndings from our laboratory suggest
that the KO mice brains have a sustained increase in NF-κB
DNA binding activity up to 24-hour post-WBI. In addition,
the SGZs of these mice have a signiﬁcantly lower level
of basal proliferation compared to age-matched WT mice
(unpublishedobservations).Theseﬁndingsarenotsurprising;
PPARα KO mice exhibit a prolonged response to inﬂamma-
tory stimuli such as lipopolysaccharide and leukotriene B4
[116, 117]. In addition, they develop a physiologically aged
phenotypeearlierinlifecomparedtotheWTmiceindicating
ar o l ef o rP P A R α in maintaining the cellular redox balance
[118].Thus,itispossiblethatthelackofPPARαenhancesthe
basal level of inﬂammation and thereby leads to a protracted
response to radiation injury. Nevertheless, the experiments
using the KO mice served as a reliable experimental control
for the oﬀ-target eﬀects of fenoﬁbrate and underlined the
importance of PPARα in radiation-induced brain injury
(Ramanan et al. unpublished data). Whether PPARγ and δ
ligands mediate similar protective eﬀects on hippocampal
neurogenesis following WBI is not yet known and is being
actively investigated in our laboratory.
8. Effect of PPAR Agonists on WBI-Induced
Cognitive Impairment
Functionally, radiation-induced brain injury is character-
ized by a progressive, cognitive impairment that severely
compromises the quality of life (QOL) of cancer patients
receiving radiotherapy. Given the increasing evidence for a
role of oxidative stress/inﬂammation in radiation-induced
brain injury, Zhao et al. tested the hypothesis that the
PPARγ agonist pioglitazone (Pio) would ameliorate the
severityofradiation-inducedcognitiveimpairmentinawell-
c h a r a c t e r i z e dr a tm o d e lo ff r a c t i o n a t e dW B I .Y o u n ga d u l t
male F344 rats were divided into ﬁve experimental groups:
(1) fractionated WBI; 40 or 45Gy γ rays delivered as eight
or nine 5Gy fractions over 4 or 4.5 weeks, respectively and
normal diet; (2) sham irradiation and normal diet; (3) WBI
plus Pio (120ppm) prior, during and for 4 or 54 weeks
postirradiation; (4) sham irradiation and Pio diet; (5) WBI
plus Pio starting 24 hours after completion of WBI. This
study found that administering Pio prior to, during, and up
to4-or54-weekspost-WBIsigniﬁcantlymitigatedtheWBI-
induced cognitive impairment as measured by the object
recognition test. However, the mechanism(s) involved in the
radiation protection by PPARγ is not known at present.
WithreferencetoPPARα,althoughwedemonstratedthat
fenoﬁbrate prevented the detrimental eﬀect of WBI on hip-
pocampal neurogenesis and inhibited microglial activation,
we were unable to use the mouse model to test whether it can
inhibit radiation-induced cognitive impairment. These mice
have a 129/sv background and perform poorly in cognitive
function tasks due to defects in their corpus callosum [119].
Currently we are using the existing rat model to investigate
whether fenoﬁbrate mitigates radiation-induced cognitive
impairment. At present, the role of PPARδ in radiation-
induced brain injury is not known and is actively being
investigated in our laboratory.
9. PutativeMechanism(s)of PPARs in
Radiation-InducedBrain Injury
Both clinical and experimental evidence point out that
the radiation-induced cognitive impairment can occur in
the absence of gross histopathological and radiographical
changes alterations [73–75]. These data suggest that more
subtle cellular/molecular and functional changes (glial acti-
vation, neural precursor, endothelial and neuronal dysfunc-
tion) as result of increased inﬂammation/oxidative stress
might play a role in the pathogenesis of radiation-induced
late eﬀects.
Based on our ﬁndings, we propose a model for the
role of PPARs in the regulation of radiation-induced
brain injury. Irradiating the brain leads to increased
proinﬂammatory response as evidenced by (1) increased
activity of NF-κB and AP-1 and (2) increased levels
of TNFα,I L - 1 β and Cox-2. Microglia probably are the
primary source of these mediators, although other cells
likely contribute to the proinﬂammatory response [107,
120]. These cytokines might diﬀuse into the extracellular
space and act on astrocytes, endothelial cells, neurons,
and neighboring microglia, initiating a cytokine signaling
cascade that alters the brain microenvironment (enhanced
neuroinﬂammation, decreased hippocampal neurogenesis)
and ultimately contributes to radiation-induced cognitive
impairment (Figure 1).
While the exact role of these proinﬂammatory mediators
in the pathogenesis of radiation-induced brain injury is
currently under investigation, a clue to their function
is suggested by studies with other brain injury models.
Although required for the normal brain development, NF-
κB and AP-1 have been shown to be dysegulated in a
number of CNS disorders. An up-regulation of c-jun activity
has been observed following neuronal injury [121]. In
addition, mutating the activating phosphorylation sites on c-
jun protects against neuronal apoptosis in the hippocampus
[122].Similarly,inanexperimentalspinalcordinjurymodel,
the p65 subunit of NF-κB was chronically activated in the
microglia, endothelial cells and neurons adjacent to the
lesion [123]. Increased levels of proinﬂammatory cytokines
have been associated with a number of neuroinﬂammatory
conditions such as Alzheimer’s disease [124], Parkinson’s
disease [125], and multiple sclerosis [126]. Experimental
augmentation of TNFα,I L - 1 β,a n dC o x - 2l e v e l sh a sb e e n
shown to induce behavioral and memory impairments in
rodents [127–129]. TNFα and IL-1β have been shown to
be potent inducers of apoptosis in oligodendrocytes and
neural progenitor cells [130–132]. These data suggest that
theelevatedlevelsofproinﬂammatorymediatorsinthebrain
following irradiation could contribute to the pathogenesis of
radiation-induced brain injury.
In a number of model systems, activation of PPARs has
beenshowntodownregulate theexpression ofproinﬂamma-
tory mediators, such as TNFα,I L - 1 β, Cox-2, and iNOS byPPAR Research 7
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Figure 1: Model for the role of PPARs in radiation-induced brain injury. Irradiation is hypothesized to modify the brain microenvironment
via the generation of an inﬂammatory and/or oxidative stress response which is also characterized by increased cell death of the neural
precursor cells residing in the neurogenic regions of the brain. This alteration in the microenvironment is proposed to play a role in
the dysfunction of the various cell-types in the brain (e.g., astrocytes, endothelial cells, microglia, neurons, and oligodendrocytes) and
the reduction in ongoing adult neurogenesis ultimately contributing to radiation-induced brain injury including cognitive impairment.
Activation of PPARs using speciﬁc ligands is hypothesized to play a role in normalizing the brain microenvironment and preserving cellular
function following irradiation in part via inhibition of proinﬂammatory signaling pathways and by upregulation of antioxidant enzyme
activities thus ameliorating the detrimental eﬀects of radiation on the brain.
interfering with the activity of transcription factors NF-κB,
AP-1, and STAT-1 (extensively reviewed in [2, 32]). More-
over, PPAR ligands have been shown to maintain the redox
balance by upregulating the expression and activity of several
antioxidant enzymes. A putative PPRE has been identiﬁed
in the rat catalase promoter, the activity and expression of
which was induced upon PPARγ ligand treatment [133].
PPARα and γ ligands downregulated phorbol ester-induced
expression of NAPDH oxidase subunits p22phox (message
level) and p47phox (protein levels), which was accompanied
by increased superoxide dismutase (SOD) activity [134,
135]. PPARδ agonists have been shown to inhibit TNFα-
induced ROS generation by upregulating expression of
antioxidant enzymes catalase, SOD-1, and thioredoxin in
human umbilical vein endothelial cells [136]. Moreover, as
describedpreviously,PPARligandscanmodulatetheseverity
ofseveralCNSdisorders.Thesedata,alongwithourﬁndings,
support the hypothesis that activation of PPARs, via anti-
inﬂammatory and/or antioxidant mechanisms, normalizes
the brain microenvironment (characterized by reduced
glial activation and preserved hippocampal neurogenesis)
following WBI contributing to the amelioration of cognitive
impairment following irradiation.
Fromourmodel,itisimportanttoappreciatethataltered
hippocampal neurogenesis and microglial activation follow-
ing WBI account for only one aspect of the pathogenesis of
radiation-inducedbraininjury.Theradiationresponseofthe
brain is complex and involves multiple pathways turned on
in multiple cell types via autocrine, paracrine, and juxtacrine
signalingmechanisms.Therefore,therelativecontributionof
other brain cells–astrocytes, endothelial cells, neurons and
oligodendrocytes– to radiation injury cannot be excluded.
In the future, investigating the radiation response of these
cells and whether PPAR ligands can prevent their cellular
dysfunction following irradiation will help shed more light
on the mechanism(s) of radiation-induced brain injury and
how it can be modulated.
10. Conclusions
Of the ∼200000 patients who receive WBI each year in
the USA, up to 50% of them will develop progressive,
cognitive impairment. There are no long-term treatment
or prevention strategies for this debilitating side eﬀect.
Although the exact mechanisms remain ill-deﬁned, increas-
ing experimental evidence suggests a role for inﬂammation
and/or oxidative stress during the pathogenesis of radiation-
induced brain injury. PPAR ligands, given their propensity
to target and modulate multiple proinﬂammatory pathways
and their ability to upregulate antioxidant enzymes, appear
to be an eﬀective therapeutic strategy to modulate late
eﬀects following WBI. PPARα ligands inhibit the radiation-
induced proinﬂammatory responses in the microglia in vitro
and prevent the detrimental eﬀect of WBI on hippocampal8 PPAR Research
neurogenesis in vivo. Moreover, the PPARγ ligand Pio
mitigated the WBI-induced cognitive impairment. Most
importantly, PPARα and γ ligands are FDA-approved and
are routinely prescribed for the treatment of several chronic
disorders such as hypertriglyceridemia, dyslipidemia, and
Type 2 diabetes [17, 137, 138]. PPARδ agonists are currently
in Phase II clinical trials for dyslipidemia [139]. Therefore,
these compounds oﬀer the promise of enhancing the quality
of life and long-term survival of cancer patients receiving
brain irradiation.
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